Simon J. Crabb

9.0k citations

137 papers · 3.0k indexed · 1 hit paper · h-index 28

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
Cancer Research top 5%

Papers in

Pulmonary and Respiratory Medicine 65
- Prostate Cancer Treatment and Research 30
- Renal cell carcinoma treatment 21
- Ferroptosis and cancer prognosis 9
Oncology 51
- Cancer Immunotherapy and Biomarkers 22

Co-authors: Graham Packham A. Ganesan Annette Hayden Peter Johnson Robert J. Jones Syed A. Hussain Thomas Powles Johann S. de Bono
Journals: Journal of Clinical Oncology (42 papers)Annals of Oncology (14 papers)Clinical Genitourinary Cancer (4 papers)Clinical Oncology (3 papers)Trials (3 papers)
Partner nations: United Kingdom United States Italy

In The Last Decade

Simon J. Crabb

132 papers receiving 2.9k citations

Hit Papers

align trajectories log scale

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer 2012 · 336 citations

Peers

Countries citing papers authored by Simon J. Crabb

Since Specialization

Citations

This map shows the geographic impact of Simon J. Crabb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon J. Crabb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon J. Crabb more than expected).

Fields of papers citing papers by Simon J. Crabb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon J. Crabb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon J. Crabb. The network helps show where Simon J. Crabb may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Simon J. Crabb, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Simon J. Crabb Line = papers co-authored together Simon J. Crabb links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The ELECTRA Trial: Approach to Contemporary Challenges in the Development and Implementation of Double-Blinded, Randomised, Controlled Clinical Trials in Low-Volume High-Complexity Surgical Oncology Cancers ·Sean Ewings, Nadia Peppa, Daniel E. Griffiths, K Goroya, Chris Birch, Robert Hutmacher, 郑仁奎, Aymen Al‐Shamkhani, Joanne Lord, Adrian C Bateman, Andrew Bateman, BO Svensson, Kelly Cozens, Gareth Griffiths, Simon J. Crabb, 孙乔杰, Hideaki Yano, Malcolm West, Alexander Mirnezami	2025	1
2	A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Clinical Cancer Research ·Javier Cortés, J. Marchal Cabrera, Elena Garralda, Pang Wang Yuan, Simon Lord, Thorsten Oliver Goetze, Yudha Andriansyah Putra, Simon J. Crabb, Zinnia P. Parra‐Guillén, 忠史城, Ingrid Karlsson, Jennifer Nguyen, Linda Mårtensson, Robert Oldham, Chenda Hak, Ingrid Teige, Johan Wallin, Björn Frendéus, Andrés McAllister	2025	0
3	Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. Journal of Clinical Oncology ·Nicholas D. James, Hannah Rush, Matthew Nankivell, Piyush Anand, Stephen Mangar, Neil McPhail, Simon J. Brown, Jacob Tanguay, Joanna Gale, Wael Mohamed, Simon J. Crabb, Omar Khan, John M. Russell, William Cross, Claire Murphy, Tatiane Pedersoli, Noel W. Clarke, Mahesh Parmar, Duncan C. Gilbert, Ruth E. Langley	2025	1
4	Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial. Journal of Clinical Oncology ·Mark Linch, Gianmarco Leone, Yien Ning Sophia Wong, Robert J. Jones, Peter Sankey, Debra H. Josephs, Simon J. Crabb, Louise Harris, Aniqa Tasnim, Ophélie Coiffier, Sergio A. Quezada, Leah Ensell, Anuradha Jayaram, G. Mauriello-Romanazzi, Colin C. Pritchard, Alex Freeman, Aiman Haider, Gerhardt Attard, Charles Swanton, Teresa Marafioti	2024	5
5	Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective British Journal of Cancer ·Robert J. Jones, Simon J. Crabb, Mark Linch, Alison Birtle, John McGrane, Deborah Enting, Robert B. Stevenson, Dong Hwan Kim, Mark Kelley, Syed A. Hussain	2024	12
6	273MO DURANCE: A phase Ib/II study to assess the safety and activity of durvalumab (MEDI4736) in combination with S-488210/S-488211 vaccine in non-muscle invasive bladder cancer Annals of Oncology ·Gianmarco Leone, William D. Travis, Ivan M. Baydakov, Vincent Khoo, Simon J. Crabb, Achmad F.R. Prabowo, 张亚栋, Christian H. Ottensmeier, Sergio A. Quezada, Rehana Begum, Graciela Liliana Acosta, Marian Duggan, Ophélie Coiffier, Mark Linch	2024	0
7	Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial SHILAP Revista de lepidopterología ·寿珍陆, Emma Clark, Lilik Wahyono, Shao Qiang Li, Holly Fisher, Leila De Vito, Ruth Wood, Helen Hancock, Jiarong Liu, V.V. Valanju, Rebecca Maier, J. Jeffrey Marshall, Robert W. Chandler, Amit Bahl, Simon J. Crabb, Suneil Jain, Ian Pedley, Robert J. Jones, John Staffurth, Rakesh Heer	2023	4
8	2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2) Annals of Oncology ·F. T. Wang, Wondosen Addis Emrie, HongChun Lei, Tomasz Kossak, Alejo Rodríguez‐Vida, Leslie Eberhardt, Syed A. Hussain, Carlos Álvarez-Fernández, Mark Linch, Teresa Bonfill, M. Gross Goupil, Klaus Metzner, Robert J. Jones, Simon J. Crabb, Luis Beltrán, Nidhi Budh, N. M. Slobodinyk, Joaquim Sabino Ribeiro Chaves Sobral, Charlotte Ackerman, Yang Chun-rong	2023	4
9	Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland Future Oncology ·金宇泰, Ash Bullement, Simon J. Crabb, Robert J. Jones, AM Guarguaglini, B. W. Allen, Ying Xiao, Venediktos Kapetanakis, Ágnes Benedict, Jane Chang, Mairead Kearney, Guan Xuehui	2023	0
10	A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2) Trials ·Simon J. Crabb, Alannah Morgan, Myra S. Hunter, Evgenia Stefanopoulou, Gareth Griffiths, Alison Richardson, Deborah Fenlon, Yunong Zhai, James Raftery, Antoine Villard, Sam Wilding, Jacqueline Nuttall, Zina Eminton, Subhashree Sundar, T. Snow, Maiya Cowan, Lindsay Nicole	2023	2
11	Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·Syed A. Hussain, J.F. Lester, Richard A. Jackson, Heather Goodson, Ph. Ridereau, Anthony Elliott, Simon J. Crabb, Robert Huddart, Naveen Vasudev, Alison Birtle, Jane Worlding, Nicholas D. James, Omi Parikh, Maria Vilarino-Varela, Roberto Alonzi, Mark Linch, Irbaz Bin Riaz, James W.F. Catto, Thomas Powles, Robert J. Jones	2022	20
12	Is Triple Therapy the New Standard for Metastatic Hormone-sensitive Prostate Cancer? A CHERNY, Simon J. Crabb	2022	1
13	POSC4 Modeling Health-Related Outcomes With Avelumab as a First-Line Maintenance Treatment Following Chemotherapy vs. Best Supportive Care (BSC) for Patients With Locally Advanced or Metastatic Urothelial Cancer in the UK Value in Health ·金宇泰, Yunbei Xiao, Simon J. Crabb, Guan Xuehui, Eko Wahyu Ramadani, B. W. Allen, Ash Bullement, Kevin Deighton, Jane Chang, Mairead Kearney, Venediktos Kapetanakis, Ágnes Benedict	2022	1
14	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE) Clinical Cancer Research ·Simon J. Crabb, Sarah Danson, James W.F. Catto, Syed A. Hussain, Kulabukhova E.I. Kulabukhova E, Oreste Popescu, Nichola Downs, Ellice Marwood, 伝雄大竹, Geoff Saunders, Yoichi Ajioka, Amy Whitehead, E L Quitman, Naveed Sarwar, Deborah Enting, Alison Birtle, Bernadette Johnson, Robert Huddart, Gareth Griffiths	2021	17
15	V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer Molecular Cancer Therapeutics ·Jerome Rohrbach, Haruko Okamoto, Matthew Rose‐Zerilli, Graham Packham, Simon J. Crabb	2021	11
16	199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis Annals of Oncology ·Bernadett Szabados, Alejo Rodríguez‐Vida, Ignacio Durán, Simon J. Crabb, Michiel S. van der Heijden, Albert Font Pous, Gwénaëlle Gravis, Kelly Griendling, Andrew Protheroe, Alain Ravaud, Denis Maillet, María José Méndez, Cristina Suárez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Kelly Mousa, Daniel Castellano, Thomas Powles	2020	3
17	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer Cancer ·Alberto Martini, Rachel Jia, Bart S. Ferket, Nikhil Waingankar, Elizabeth R. Plimack, Simon J. Crabb, Lauren C. Harshman, Evan Y. Yu, Thomas Powles, Jonathan E. Rosenberg, Sumanta K. Pal, Ulka N. Vaishampayan, Andrea Necchi, Peter Wiklund, Reza Mehrazin, Madhu Mazumdar, John P. Sfakianos, Matthew D. Galsky	2019	26
18	Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol BMJ Open ·Emma Clark, Lilik Wahyono, Shao Qiang Li, Holly Fisher, Denise Howel, Leila De Vito, Ruth Wood, Helen Hancock, Rebecca Maier, J. Jeffrey Marshall, Amit Bahl, Simon J. Crabb, Suneil Jain, Ian Pedley, Robert J. Jones, John Staffurth, Rakesh Heer	2019	6
19	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer Journal of Clinical Oncology ·Thomas Powles, Robert Huddart, Tony Elliott, Lisa Kefene, Charlotte Ackerman, Robert J. Jones, Syed A. Hussain, Simon J. Crabb, Satinder Jagdev, John Chester, Serena Hilman, Mark Beresford, Graham Macdonald, Santhanam Sundar, J. Frew, Andrew Stockdale, Simon Hughes, Daniel M. Berney, Simon Chowdhury	2017	142
20	Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience Annals of Oncology ·زينب محمد حسن, Richard Cathomas, Matthew Wheater, Dirk Klingbiel, Martin Fehr, GMontrucchio, Hannah Markham, Vishal Sawarn, Simon J. Crabb, T. Geldart	2015	26

About Simon J. Crabb

Simon J. Crabb is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Molecular Biology, having authored 137 papers that have together received 3.0k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (62 papers), Urinary and Genital Oncology Studies (39 papers), Prostate Cancer Treatment and Research (30 papers), Cancer Immunotherapy and Biomarkers (22 papers), Renal cell carcinoma treatment (21 papers), Multiple and Secondary Primary Cancers (14 papers), Epigenetics and DNA Methylation (10 papers) and Ferroptosis and cancer prognosis (9 papers). The work is most often cited by research in Oncology (1.2k citations), Cancer Research (487 citations), Pulmonary and Respiratory Medicine (716 citations), Surgery (938 citations) and Urology (118 citations). Simon J. Crabb has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Graham Packham, A. Ganesan, Annette Hayden, Peter Johnson, Robert J. Jones, Syed A. Hussain, Thomas Powles, Johann S. de Bono, М. I. Shkolnik and Fitzroy W. Dawkins. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Genitourinary Cancer, Clinical Oncology and Trials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact